1. Dysregulation of MMP2-dependent TGF-ß2 activation impairs fibrous cap formation in type 2 diabetes-associated atherosclerosis.
- Author
-
Singh P, Sun J, Cavalera M, Al-Sharify D, Matthes F, Barghouth M, Tengryd C, Dunér P, Persson A, Sundius L, Nitulescu M, Bengtsson E, Rattik S, Engelbertsen D, Orho-Melander M, Nilsson J, Monaco C, Goncalves I, and Edsfeldt A
- Subjects
- Humans, Male, Female, Animals, Middle Aged, Aged, Collagen metabolism, Extracellular Matrix metabolism, Mice, Cell Differentiation, Diabetes Mellitus, Type 2 metabolism, Diabetes Mellitus, Type 2 complications, Diabetes Mellitus, Type 2 pathology, Transforming Growth Factor beta2 metabolism, Matrix Metalloproteinase 2 metabolism, Plaque, Atherosclerotic metabolism, Plaque, Atherosclerotic pathology, Muscle, Smooth, Vascular metabolism, Muscle, Smooth, Vascular pathology, Myocytes, Smooth Muscle metabolism, Myocytes, Smooth Muscle pathology, Atherosclerosis metabolism, Atherosclerosis pathology
- Abstract
Type 2 diabetes is associated with cardiovascular disease, possibly due to impaired vascular fibrous repair. Yet, the mechanisms are elusive. Here, we investigate alterations in the fibrous repair processes in type 2 diabetes atherosclerotic plaque extracellular matrix by combining multi-omics from the human Carotid Plaque Imaging Project cohort and functional studies. Plaques from type 2 diabetes patients have less collagen. Interestingly, lower levels of transforming growth factor-ß distinguish type 2 diabetes plaques and, in these patients, lower levels of fibrous repair markers are associated with cardiovascular events. Transforming growth factor-ß2 originates mostly from contractile vascular smooth muscle cells that interact with synthetic vascular smooth muscle cells in the cap, leading to collagen formation and vascular smooth muscle cell differentiation. This is regulated by free transforming growth factor-ß2 which is affected by hyperglycemia. Our findings underscore the importance of transforming growth factor-ß2-driven fibrous repair in type 2 diabetes as an area for future therapeutic strategies., Competing Interests: Competing interests: A.E. reports consulting fees from Novo Nordisk, Sanofi and Amgen, but this has not had any relationship with the current study or affected the design/outcome of the study., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF